Effect of risperidone on acute methamphetamine-induced hyperthermia in rats

Drug and Alcohol Dependence

Volumn 111, Issue 3, 2010, Pages 241-249

  Shioda, Katsutoshi ^a,b   Nisijima, Koichi ^a   Yoshino, Tatsuki ^a   Kato, Satoshi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Tamura City Miyakoji Clinic   (Japan)

Author keywords

Dopamine; Glutamate; Methamphetamine; Nitric oxide; Risperidone; Serotonin

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; HALOPERIDOL; KETANSERIN; L 741626; METHAMPHETAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NITRATE; NITROGEN DIOXIDE; R 96544; RISPERIDONE; RITANSERIN; SEROTONIN; SEROTONIN 2A ANTAGONIST; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG MECHANISM; HYPERTHERMIA; HYPOTHALAMUS; LOW DRUG DOSE; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; FEVER; MALE; METHAMPHETAMINE; RATS; RATS, WISTAR; RISPERIDONE;

RATTUS;

EID: 77957313043     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.05.001     Document Type: Article

References (54)

1. Abekawa T., Ohmori T., Honda M., Ito K., Koyama T. Effect of low doses of L-NAME on methamphetamine-induced dopaminergic depletion in the rat striatum. J. Neural Transm. 2001, 108:1219-1230.
2. Ago Y., Nakamura S., Kajita N., Uda M., Hashimoto H., Baba A., Matsuda T. Ritanserin reverses repeated methamphetamine-induced behavioral and neurochemical sensitization in mice. Synapse 2007, 61:757-763.
3. Albers D.S., Sonsalla P.K. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J. Pharmacol. Exp. Ther. 1995, 275:1104-1114.
4. 2 receptors. Neuropsychopharmacology 2002, 24:40-52.
5. 1-adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse. Br. J. Pharmacol. 2008, 153:591-597.
6. Blessing W.W. Clozapine increases cutaneous blood flow and reduced sympathetic cutaneous vasomotor altering response (SCVARs) in rats: comparison with effects of haloperidol. Psychopharmacology 2005, 181:518-528.
7. Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker W., Holson R.R. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Ther. 1994, 268:1571-1580.
8. 2 receptor antagonists with d-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. Synapse 2005, 56:84-93.
9. Bronstein D.M., Hong J.S. Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality. J. Pharmacol. Exp. Ther. 1995, 274:943-950.
10. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14:87-96.
11. Callahan B.T., Ricaurte G.A. Effect of 7-nitroindazole on body temperature and methamphetamine-induced dopamine toxicity. Neuroreport 1998, 9:2691-2695.
12. Chan P., Chen J.H., Lee M.H., Deng J.F. Fatal and nonfatal methamphetamine intoxication in the intensive care unit. J. Toxicol. Clin. Toxicol. 1994, 32:147-155.
13. 1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity. J. Biol. Chem. 2003, 278:28089-28100.
14. Chen W.J., Fu T.C., Ting T.T., Huang W.L., Tang G.M., Hsiao C.K., Chen C.Y. Use of ecstasy and other psychoactive substances among school-attending adolescents in Taiwan: national surveys 2004-2006. BMC Pub. Health 2009, 9:27. http://www.biomedcentral.com/1471-2458/9/27.
15. Davidson C., Gow A.J., Lee T.H., Ellinwood E.H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Brain Res. Rev. 2001, 36:1-22.
16. Doyle J.R., Yamamoto B.K. Serotonin 2 receptor modulation of hyperthermia, corticosterone, and hippocampal serotonin depletions following serial exposure to chronic stress and methamphetamine. Psychoneuroendocrinology 2010, 35:629-633.
17. 2 antagonist. Pharmacol. Biochem. Behav. 1997, 58:1015-1019.
18. Gołembiowska K., Konieczny J., Wolfarth S., Ossowska K. Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats. Neuropharmacology 2003, 45:484-492.
19. Greene S.L., Kerr F., Braitberg G. Review article: amphetamines and related drugs of abuse. Emerg. Med. Aust. 2008, 20:391-402.
20. 2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology 2005, 178:505-513.
21. 2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur. J. Pharmacol. 1993, 23:291-296.
22. Ishigami A., Kubo S., Gotohda T., Tokunaga I. The application of immunohistochemical findings in the diagnosis in methamphetamine-related death-two forensic autopsy cases. J. Med. Invest. 2003, 50:112-116.
23. Itzhak Y., Ali S.F. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J. Neurochem. 1996, 67:1770-1773.
24. Itzhak Y., Martin J.L., Ail S.F. nNOS inhibitors attenuate methamphetamine-induced dopaminergic neurotoxicity but not hyperthermia in mice. Neuroreport 2000, 11:2943-2946.
25. Kalasinsky K.S., Hugel J., Kish S.J. Use of MDA (the "love drug" ) and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J. Forensic Sci. 2004, 49:1106-1112.
26. Kinner S.A., Degenhardt L. Crystal methamphetamine smoking among regular ecstasy users in Australia: increases in use and associations with harm. Drug Alcohol Rev. 2008, 27:292-300.
27. Kojima T., Une I., Yashiki M., Noda J., Sakai K., Yamamoto K. A fatal methamphetamine poisoning associated with hyperpyrexia. Forensic Sci. Int. 1984, 24:87-93.
28. Kuczenski R., Segal D.S., Cho A.K., Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J. Neurosci. 1995, 15:1308-1317.
29. 2A receptors. Psychopharmacology 1995, 117:193-199.
30. Nash J.F., Yamamoto B.K. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 1992, 581:237-243.
31. 1-like dopamine receptors. J. Neurosci. 1996, 16:1591-1604.
32. Nisijima K., Yoshino T., Ishiguro T. Risperidone counteracts lethality in an animal model of the serotonin syndrome. Psychopharmacology (Berl) 2000, 150:9-14.
33. 2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 2001, 890:23-31.
34. 2A receptor antagonist R-102444. Eur. J. Pharmacol. 2002, 457:107-114.
35. Ohmori T., Abekawa T., Koyama T. The role of glutamate in behavioral and neurotoxic effects of methamphetamine. Neurochem. Int. 1996, 29:301-307. (review).
36. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, New York. 2nd ed.
37. 2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 2002, 26:311-324.
38. Sammut S., Dec A., Mitchell D., Linardakis J., Ortiguela M., West A.R. Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D(1/5) receptor-dependent mechanism. Neuropsychopharmacology 2006, 31:493-505.
39. Sanchez V., Zeini M., Camarero J., O'Shea E., Bosca L., Green A.R., Colado M.I. AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum. J. Neurochem. 2003, 85:515-524. The nNOS inhibitor.
40. Schotte A., Jansen P.F., Gommeren W., Luyten W.H., van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996, 124:57-73.
41. Schmidt A.W., Lebel L.A., Howard H.R., Zorn S.H. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. 2001, 425:197-201.
42. Sheng P., Cerrut I.C., Ali S., Cadet J.L. Nitric oxide is a mediator of methamphetamine (METH)-induced neurotoxicity. In vitro evidence from primary cultures of mesencephalic cells. Ann. N. Y. Acad. Sci. 1996, 801:174-186.
43. Shimada A., Yamaguchi K., Yanagita T. Neurochemical analysis of the psychotoxicity of methamphetamine and cocaine by microdialysis in the rat brain. Ann. N. Y. Acad. Sci. 1996, 801:361-370.
44. Shioda K., Nisijima K., Yoshino T., Kato S. Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:633-640.
45. Shioda K., Nisijima K., Yoshino T., Kuboshima K., Iwamura T., Yui K., Kato S. Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurotoxicology 2008, 29:1030-1036.
46. Stahl S.M., Shayegan D.K. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J. Clin. Psychiatry 2003, 64:6-12.
47. Stephans S.E., Yamamoto B.K. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 1994, 17:203-209.
48. 1A receptor agonist on lordosis behavior. Pharmacol. Biochem. Behav. 2003, 76:63-73.
49. 2C receptor agonists in the pigeon. Behav. Pharmacol. 2000, 11:355-364.
50. 2A receptor blockade. CNS Neurol. Disord. Drug Targets 2006, 5:445-452.
51. Yamada J., Sugimoto Y., Wakita H., Horisaka K. The involvement of serotonergic and dopaminergic systems in hypothermia induced in mice by intracerebroventricular injection of serotonin. Jpn. J. Pharmacol. 1998, 48:145-148.
52. Yamada K., Nabeshima T. Simultaneous measurement of nitrite and nitrate levels as indices of nitric oxide release in the cerebellum of conscious rats. J. Neurochem. 1997, 68:1234-1243.
53. Yamada K., Nabeshima T. Two pathways of nitric oxide production through glutamate receptors in the rat cerebellum in vivo. Neurosci. Res. 1997, 28:93-102.
54. Yamawaki S., Laim H., Horita A. Dopaminergic and serotonergic mechanisms of thermoregulation: mediation of thermal effects of apomorphine and dopamine. J. Pharmacol. Exp. Ther. 1983, 227:383-388.